199 related articles for article (PubMed ID: 28515245)
1. Biomarker-Based Treatment Selection in Non-Small Cell Lung Cancer.
Akerley W
J Natl Compr Canc Netw; 2017 May; 15(5S):689-691. PubMed ID: 28515245
[TBL] [Abstract][Full Text] [Related]
2. What, When, and How of Biomarker Testing in Non-Small Cell Lung Cancer.
Riely GL
J Natl Compr Canc Netw; 2017 May; 15(5S):686-688. PubMed ID: 28515244
[TBL] [Abstract][Full Text] [Related]
3. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
4. [Targeted therapy and precision medicine : More than just words in the treatment of lung cancer].
Heigener DF; Horn M; Reck M
Internist (Berl); 2016 Dec; 57(12):1243-1249. PubMed ID: 27587193
[TBL] [Abstract][Full Text] [Related]
5. Molecular Testing Turnaround Time in Non-Small-Cell Lung Cancer: Monitoring a Moving Target.
VanderLaan PA; Chen Y; DiStasio M; Rangachari D; Costa DB; Heher YK
Clin Lung Cancer; 2018 Sep; 19(5):e589-e590. PubMed ID: 29798809
[No Abstract] [Full Text] [Related]
6. A Radiologist's Guide to the Changing Treatment Paradigm of Advanced Non-Small Cell Lung Cancer: The ASCO 2018 Molecular Testing Guidelines and Targeted Therapies.
Chen L; Smith DA; Somarouthu B; Gupta A; Gilani KA; Ramaiya NH
AJR Am J Roentgenol; 2019 Nov; 213(5):1047-1058. PubMed ID: 31361530
[No Abstract] [Full Text] [Related]
7. [Targeted therapies in non-small cell lung cancer in 2014].
Leduc C; Besse B
Rev Mal Respir; 2015 Feb; 32(2):182-92. PubMed ID: 25704901
[TBL] [Abstract][Full Text] [Related]
8. Personalised medicine for nonsmall cell lung cancer.
Mascaux C; Tomasini P; Greillier L; Barlesi F
Eur Respir Rev; 2017 Dec; 26(146):. PubMed ID: 29141962
[TBL] [Abstract][Full Text] [Related]
9. EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs.
Liang Z; Cheng Y; Chen Y; Hu Y; Liu WP; Lu Y; Wang J; Wang Y; Wu G; Ying JM; Zhang HL; Zhang XC; Wu YL
Cancer Lett; 2017 Sep; 403():186-194. PubMed ID: 28642172
[TBL] [Abstract][Full Text] [Related]
10. Blood-based tumour mutational burden analysis in NSCLC.
Das M
Lancet Oncol; 2018 Sep; 19(9):e446. PubMed ID: 30122616
[No Abstract] [Full Text] [Related]
11. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.
Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Expert Rev Mol Diagn; 2017 Oct; 17(10):933-942. PubMed ID: 28838271
[TBL] [Abstract][Full Text] [Related]
12. Management and future directions in non-small cell lung cancer with known activating mutations.
Gerber DE; Gandhi L; Costa DB
Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
[TBL] [Abstract][Full Text] [Related]
13. [Personalized therapy of lung cancer - current standard and future challenges].
Riedel R; Wolf J
Dtsch Med Wochenschr; 2017 Nov; 142(22):1660-1668. PubMed ID: 29078211
[TBL] [Abstract][Full Text] [Related]
14. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC
Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220
[TBL] [Abstract][Full Text] [Related]
15. The Evolving Role of Biomarkers in Personalized Lung Cancer Therapy.
Sharma J; Shum E; Chau V; Paucar D; Cheng H; Halmos B
Respiration; 2017; 93(1):1-14. PubMed ID: 27894113
[No Abstract] [Full Text] [Related]
16. [The molecular markers related to personalized therapy of non-small cell lung cancer].
Guo N; Yu C; Yu C
Zhongguo Fei Ai Za Zhi; 2011 Mar; 14(3):292-6. PubMed ID: 21426677
[No Abstract] [Full Text] [Related]
17. EGFR mutations in lung cancer: from tissue testing to liquid biopsy.
Fenizia F; De Luca A; Pasquale R; Sacco A; Forgione L; Lambiase M; Iannaccone A; Chicchinelli N; Franco R; Rossi A; Morabito A; Rocco G; Piccirillo MC; Normanno N
Future Oncol; 2015; 11(11):1611-23. PubMed ID: 26043215
[TBL] [Abstract][Full Text] [Related]
18. A survey of Japanese thoracic oncologists' perception of diagnostic and treatment strategies for EGFR mutant or EML4-ALK fusion non-small cell lung cancer.
Hotta K; Kiura K; Tabata M; Takigawa N; Tanimoto M; Ueoka H
Chest; 2014 Dec; 146(6):e222-e225. PubMed ID: 25451370
[No Abstract] [Full Text] [Related]
19. Improving Selection Criteria for ALK Inhibitor Therapy in Non-Small Cell Lung Cancer: A Pooled-Data Analysis on Diagnostic Operating Characteristics of Immunohistochemistry.
Jiang L; Yang H; He P; Liang W; Zhang J; Li J; Liu Y; He J
Am J Surg Pathol; 2016 May; 40(5):697-703. PubMed ID: 26825369
[TBL] [Abstract][Full Text] [Related]
20. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance.
Jotte RM; Spigel DR
Cancer Med; 2015 Nov; 4(11):1621-32. PubMed ID: 26310719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]